Home › Employers › Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc.: H-1B salaries and sponsorship
Aligos Therapeutics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $230,000.
Does Aligos Therapeutics, Inc. sponsor H-1B visas?
Aligos Therapeutics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Feb 17, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Director of Clinical Operations | 2 | $239,041 |
| Scientist | 1 | $131,019 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | $131,019 |
| FY2024 | 1 | $230,000 |
| FY2026 | 1 | $248,082 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Director of Clinical Operations | $248,082–$286,000 E-3 · Level III | San Francisco, CA | Feb 17, 2026 | Aug 1, 2026 | Certified |
| Director of Clinical Operations | $230,000 E-3 | South San Francisco, CA | Jul 12, 2024 | Sep 1, 2024 | Certified |
| Scientist | $131,019–$155,000 Level III | South San Francisco, CA | Jun 9, 2022 | Sep 2, 2022 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).